Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:34 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 998 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Comparison control condition Clear all

Conditions: Acute Coronary Syndrome
Interventions: Inclisiran; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 88
States / cities: Jonesboro, Arkansas • Bakersfield, California • Fresno, California + 75 more

Conditions: Chronic Kidney Disease (CKD), Health Communication, Patient Comprehension
Interventions: Chronic Kidney Disease (CKD) Lab Result Communication Tool; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 65 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Recurrent Acute Rhinosinusitis
Interventions: balloon sinus dilation, medical therapy; Device · Other
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 19 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 5
States / cities: Birmingham, Alabama • Atlanta, Georgia • Las Vegas, Nevada + 2 more

Conditions: Depression
Interventions: 6(S)-5-MTHF(Deplin), Placebo; Other
Lead sponsor: George I. Papakostas; Other
Eligibility: 18 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 6
States / cities: San Diego, California • Chicago, Illinois • Boston, Massachusetts + 3 more

Conditions: Attention-Deficit/Hyperactivity Disorder
Interventions: Lisdexamfetamine Dimesylate, Atomoxetine Hydrochloride; Drug
Lead sponsor: Shire; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 34
States / cities: Dothan, Alabama • Little Rock, Arkansas • Colton, California + 31 more

Conditions: Plasma Cell Myeloma
Interventions: Power drill, Jamshidi needle; Device
Lead sponsor: Emory University; Other
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Olodaterol (BI 1744), Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 644 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 28
States / cities: Mobile, Alabama • Wheat Ridge, Colorado • Waterbury, Connecticut + 23 more

Conditions: Lymphocyte Depletion
Interventions: SBRT with additional treatment planning dose optimization, SBRT with standard of care planning only, Blood Draws; Radiation · Diagnostic Test
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Lung Non-Squamous Non-Small Cell Carcinoma, Radiation-Induced Pneumonitis, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions: Durvalumab, Nintedanib, Placebo, Quality-of-Life Assessment; Biological · Drug · Other + 1 more
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Hypertension
Interventions: Audit and Feedback, Pharmacist E-Detailing; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 79 Years
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Dry Eye Syndromes, Keratoconjunctivitis Sicca
Interventions: KPI-121, Placebo; Drug
Lead sponsor: Kala Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 11
States / cities: Artesia, California • Mission Hills, California • Rancho Cordova, California + 8 more

Conditions: Crohn's Disease
Interventions: SHR0302, Placebos; Drug
Lead sponsor: Reistone Biopharma Company Limited; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 6
States / cities: Clearwater, Florida • Lake Wales, Florida • Tampa, Florida + 3 more

Conditions: Upper Airway Obstruction
Interventions: Physostigmine, Oxygen, Placebo; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Breast Cancer
Interventions: MBSR(BC) 6 Week Program, BCES 6 Week Program; Behavioral
Lead sponsor: University of South Florida; Other
Eligibility: 21 Years and older · Female only
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 5
States / cities: Sarasota, Florida • Tampa, Florida

Conditions: Melanoma
Interventions: In-person counseling, Workbook, Tablet Computer-Based Education; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Aclidinium bromide, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 110
States / cities: Birmingham, Alabama • Muscle Shoals, Alabama • Pell City, Alabama + 94 more

Conditions: Trapeziometacarpal Arthritis
Interventions: Decision Aid; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Patient Decision Aids, Congenital Heart Disease, Congenital Heart Defect
Interventions: Decision Aid, Values Clarification Exercise; Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 2
States / cities: Salt Lake City, Utah

Conditions: Adverse Drug Event
Interventions: Over the counter drug labels; Other
Lead sponsor: Michigan State University; Other
Eligibility: 65 Years to 110 Years
Enrollment: 420 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: East Lansing, Michigan

Conditions: Diabetes Type 2
Interventions: Insulin-Levemir, Exenatide-Bayetta, Insulin-Levemir and Exenatide-Bayetta, SenseWear Pro3® armband, DexCom CGM; Drug · Device
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Washington D.C., District of Columbia

Conditions: Sickle Cell Disease, Sickle Cell Crisis, Vaso-Occlusive Crises
Interventions: Comprehensive Care Plan; Other
Lead sponsor: Valley Anesthesiology Consultants; Other
Eligibility: 12 Years to 18 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: CHOLELITHIASIS
Interventions: Single-port cholecystectomy, Four-port laparoscopic cholecystectomy; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Exercise Recovery, Physical Performance Parameters, Muscle Damage, Cognition, Blood Biomarkers, Stress
Interventions: Pork-Based Protein Ready-to-Eat Meals, Plant-Based Protein Ready-to-Eat Meals, Carbohydrate-Focused Lower-Protein Ready-to-Eat Meals; Other
Lead sponsor: Sam Houston State University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Fort Worth, Texas • Huntsville, Texas

Conditions: Post Traumatic Stress Disorder, Depression, Emotion Regulation
Interventions: Brief Peer Supported webSTAIR; Other
Lead sponsor: Palo Alto Veterans Institute for Research; Other
Eligibility: 21 Years to 80 Years
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Palo Alto, California

Search by objective public record fields.

Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome

Patient-centered Precision Medicine Lab Result Communication for Older Adults

Comparison of Balloon Sinuplasty In-Office Versus Medical Management for Recurrent Acute Sinusitis Patients (CABERNET)

Study of 6(S)-5-MTHF Among Selective Serotonin Reuptake Inhibitor-Resistant Outpatients With Major Depressive Disorder

Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate

Evaluating Effectiveness of Powered Drill Bone Marrow Biopsy

12 / 48 wk Pivotal PFT vs PBO in COPD II

Lymphocyte Depletion and Change in Lymphocyte Functionality

Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy

Personalizing Intervention to Reduce Clinical Inertia in the Treatment of Hypertension

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease

A Phase II Study in Patients With Moderate to Severe Active Crohn's Disease

Phamacological Reversal of Airway Instability During Sedation

Efficacy of MBSR Treatment of Cognitive Impairment Among Breast Cancer Survivors

A Comparison of Interventions to Teach Melanoma Patients Skin Self-examination

Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)

The Effect of Review of a Decision Aid Prior to the Appointment on Decisional Conflict Compared to Usual Care in the Treatment of Trapeziometacarpal (TMC) Arthritis

Improving Patient and Family Health Using Family-Centered Outcomes and Shared Decision-Making

Over-the-counter (OTC) Labels for Older Adults

Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment

A Comprehensive Care Plan for Pediatric Patients With Vaso-Occlusive Crises

A Comparison of Single Port and Four Port Laparoscopic Gallbladder Removal

Effects of Pork Protein on Recovery Following Simulated Fireground Activity

Brief Peer Supported webSTAIR Compared to Enhanced Wait List